File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40)

TitleReduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40)
Authors
KeywordsAlzheimer's disease
Neuropeptide Y
β-Amyloid
Issue Date1999
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/brainresbull
Citation
Brain Research Bulletin, 1999, v. 50 n. 4, p. 251-262 How to Cite?
AbstractThe present study investigated the neurochemical and behavioural sequelae following chronic intracerebroventricular infusion of β-amyloid (1- 40) in rats. β-amyloid was either infused intermittently via implanted cannulae on the day of operation and subsequently on postsurgical days 4, 7, 10, and 13 (Experiment 1), or continuously using osmotic pumps for 14 days (Experiment 2). The same amount of β-amyloid was delivered under both infusion regimes. In both experiments, β-amyloid infusion led to severe deficits in the acquisition of a spatial reference memory task conducted on postoperative days 10 to 14. The animals were sacrificed on the postoperative day 15 for neurochemical analyses. These included radioenzymatic and radioimmunoassays, designed to determine choline acetyltransferase activity and the contents of neuropeptides (somatostatin, substance P, and neuropeptide Y), respectively. Experiment 2 also included solution- hybridisation-RNAase protection assay for preprosomatostatin mRNA quantification. There was a significant reduction in choline acetyltransferase activity and in the levels of substance P as well as somatostatin and preprosomatostatin mRNA in the cortical mantle of β- amyloid-treated rats, compared to controls in both experiments. Appreciable reductions in choline acetyltransferase activity and somatostatin level were also apparent in the hippocampus. In contrast, β-amyloid infusion did not significantly affect the brain level of neuropeptide Y. The present study demonstrated that chronic infusion of β-amyloid can lead to a reduction in the levels of selected neuropeptides resembling the pattern seen in Alzheimer's disease patients.
Persistent Identifierhttp://hdl.handle.net/10722/171662
ISSN
2023 Impact Factor: 3.5
2023 SCImago Journal Rankings: 1.008
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNag, Sen_US
dc.contributor.authorYee, BKen_US
dc.contributor.authorTang, Fen_US
dc.date.accessioned2012-10-30T06:16:13Z-
dc.date.available2012-10-30T06:16:13Z-
dc.date.issued1999en_US
dc.identifier.citationBrain Research Bulletin, 1999, v. 50 n. 4, p. 251-262en_US
dc.identifier.issn0361-9230en_US
dc.identifier.urihttp://hdl.handle.net/10722/171662-
dc.description.abstractThe present study investigated the neurochemical and behavioural sequelae following chronic intracerebroventricular infusion of β-amyloid (1- 40) in rats. β-amyloid was either infused intermittently via implanted cannulae on the day of operation and subsequently on postsurgical days 4, 7, 10, and 13 (Experiment 1), or continuously using osmotic pumps for 14 days (Experiment 2). The same amount of β-amyloid was delivered under both infusion regimes. In both experiments, β-amyloid infusion led to severe deficits in the acquisition of a spatial reference memory task conducted on postoperative days 10 to 14. The animals were sacrificed on the postoperative day 15 for neurochemical analyses. These included radioenzymatic and radioimmunoassays, designed to determine choline acetyltransferase activity and the contents of neuropeptides (somatostatin, substance P, and neuropeptide Y), respectively. Experiment 2 also included solution- hybridisation-RNAase protection assay for preprosomatostatin mRNA quantification. There was a significant reduction in choline acetyltransferase activity and in the levels of substance P as well as somatostatin and preprosomatostatin mRNA in the cortical mantle of β- amyloid-treated rats, compared to controls in both experiments. Appreciable reductions in choline acetyltransferase activity and somatostatin level were also apparent in the hippocampus. In contrast, β-amyloid infusion did not significantly affect the brain level of neuropeptide Y. The present study demonstrated that chronic infusion of β-amyloid can lead to a reduction in the levels of selected neuropeptides resembling the pattern seen in Alzheimer's disease patients.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/brainresbullen_US
dc.relation.ispartofBrain Research Bulletinen_US
dc.rightsBrain Research Bulletin. Copyright © Elsevier Inc.-
dc.subjectAlzheimer's disease-
dc.subjectNeuropeptide Y-
dc.subjectβ-Amyloid-
dc.subject.meshAmyloid Beta-Peptides - Pharmacologyen_US
dc.subject.meshAnalysis Of Varianceen_US
dc.subject.meshAnimalsen_US
dc.subject.meshCerebral Cortex - Drug Effects - Metabolismen_US
dc.subject.meshCerebral Ventriclesen_US
dc.subject.meshCholine O-Acetyltransferase - Metabolismen_US
dc.subject.meshHippocampus - Drug Effects - Metabolismen_US
dc.subject.meshInfusion Pumps, Implantableen_US
dc.subject.meshInfusions, Parenteralen_US
dc.subject.meshMaleen_US
dc.subject.meshMaze Learning - Drug Effectsen_US
dc.subject.meshOsmotic Pressureen_US
dc.subject.meshPeptide Fragments - Pharmacologyen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Sprague-Dawleyen_US
dc.subject.meshSomatostatin - Metabolismen_US
dc.subject.meshSubstance P - Metabolismen_US
dc.titleReduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40)en_US
dc.typeArticleen_US
dc.identifier.emailTang, F:ftang@hkucc.hku.hken_US
dc.identifier.authorityTang, F=rp00327en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0361-9230(99)00196-3en_US
dc.identifier.pmid10582523-
dc.identifier.scopuseid_2-s2.0-0032730839en_US
dc.identifier.hkuros53244-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032730839&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume50en_US
dc.identifier.issue4en_US
dc.identifier.spage251en_US
dc.identifier.epage262en_US
dc.identifier.isiWOS:000083663000004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridNag, S=7103093193en_US
dc.identifier.scopusauthoridYee, BK=7006955693en_US
dc.identifier.scopusauthoridTang, F=7201979770en_US
dc.identifier.issnl0361-9230-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats